SU6656

SU6656
Names
	IUPAC name (3Z)-N,N-Dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-2,3-dihydro-1H-indole-5-sulfonamide
Identifiers
CAS Number	330161-87-0 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL605003;
ChemSpider	4471568;
IUPHAR/BPS	6044;
PubChem CID	5312137;
	InChI InChI=1S/C19H21N3O3S/c1-22(2)26(24,25)14-7-8-18-15(11-14)16(19(23)21-18)10-13-9-12-5-3-4-6-17(12)20-13/h7-11,20H,3-6H2,1-2H3,(H,21,23)/b16-10-;
	SMILES O=S(=O)(c1cc\2c(cc1)NC(=O)C/2=C/c3cc4c([nH]3)CCCC4)N(C)C;
Properties
Chemical formula	C19H21N3O3S
Molar mass	371.46 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

SU6656 is a Src family kinase inhibitor developed by the biotechnology company SUGEN Inc (a subsidiary of Pharmacia) in 2000.^[1] SU6656 was initially identified as a Src kinase inhibitor by virtue of its ability to reverse an effect that an activated mutant form of Src (hu SRC Y530F) has on the actin cytoskeleton, namely the formation of podosome rosettes, otherwise known as invadopodia. SU6656 was initially published as a Src family kinase inhibitor with selectivity relative to Platelet-derived growth factor receptor Tyrosine kinase.^[2] Subsequent studies have confirmed that SU6656 is relatively selective for Src family kinases, but some additional biochemical activities have been identified including: BRSK2, AMPK, Aurora C, Aurora B, CaMKKβ.^[3] The inhibition of these kinases in biochemical reactions in vitro does not necessarily indicate that these kinases are targets of SU6656 in cells.

SU6656 has been used primarily as a research tool to investigate the function of Src family kinases in cellular signal transduction processes and biology.

References

↑ United States Patent US 611437 . September 5, 2000, Tang; Peng Cho, Sun; Li, McMahon; Gerald; Blake; Robert A. 3-(CYCLOHEXANOHETEROARYLIDENYL)-2-INDOLINONE PROTEIN TYROSINE KINASE INHIBITORS
↑ Blake, R. A., M. A. Broome; et al. (2000). "SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling". Mol Cell Biol. 20 (23): 9018–9027. doi:10.1128/MCB.20.23.9018-9027.2000. PMC 86555. PMID 11074000.{{cite journal}}: CS1 maint: multiple names: authors list (link)
↑ Bain, J., L. Plater; et al. (2007). "The selectivity of protein kinase inhibitors: a further update". Biochem J. 408 (3): 297–315. doi:10.1042/BJ20070797. PMC 2267365. PMID 17850214.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] United States Patent US 611437 . September 5, 2000, Tang; Peng Cho, Sun; Li, McMahon; Gerald; Blake; Robert A. 3-(CYCLOHEXANOHETEROARYLIDENYL)-2-INDOLINONE PROTEIN TYROSINE KINASE INHIBITORS

[2] Blake, R. A., M. A. Broome; et al. (2000). "SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling". Mol Cell Biol. 20 (23): 9018–9027. doi:10.1128/MCB.20.23.9018-9027.2000. PMC 86555. PMID 11074000.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[3] Bain, J., L. Plater; et al. (2007). "The selectivity of protein kinase inhibitors: a further update". Biochem J. 408 (3): 297–315. doi:10.1042/BJ20070797. PMC 2267365. PMID 17850214.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]